Scholars Central

Conference abstractPublished 11 Oct 2021

Reposition of Montelukast either Alone or In Combination with Levocetirizine against SARS-CoV-2

Authors: Dipankar Bhattachayya

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), anorher two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Toxicology Journal
  • SubjectPharmaceutical Sciences
  • SubjectToxicology
  • BylineArticles whose byline prints “Dipankar Bhattachayya”